Foundayo (Orforglipron): Everything You Need to Know (2026)
Foundayo is the brand name for orforglipron, Eli Lilly's once-daily GLP-1 weight loss pill approved by the FDA in April 2026. Learn how it works, expected results, cost, and how it compares to Wegovy and Zepbound.
What is orforglipron?
Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on April 1, 2026, making it the first pill-based GLP-1 weight loss medication from Lilly. Unlike injectable GLP-1 drugs such as Wegovy and Zepbound that require weekly shots, orforglipron comes as a tablet you take by mouth each day.
What makes orforglipron scientifically interesting is that it is a non-peptide small molecule. Most GLP-1 medications, including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), are peptide-based drugs that require complex manufacturing processes. Small molecules like orforglipron can be produced more efficiently, which could eventually translate to lower costs and wider availability.
ClearlyMeds is an independent editorial team. Revenue never influences our rankings, and every guide is written to help readers understand tradeoffs in plain English rather than push a single provider.
For patients who have been interested in GLP-1 treatment but put off by the idea of injections, orforglipron represents a meaningful shift. Needle phobia is one of the most commonly cited reasons people avoid or delay starting GLP-1 therapy, and a daily pill eliminates that barrier entirely.
- FDA approved April 1, 2026
- First oral GLP-1 from Eli Lilly
- Non-peptide small molecule (cheaper to manufacture than peptides)
- Once-daily pill, no injection required
How orforglipron works
Orforglipron activates GLP-1 receptors in the body, which triggers several metabolic effects: it slows gastric emptying, reduces appetite, increases feelings of fullness, and helps regulate blood sugar. These are the same mechanisms that make injectable GLP-1 medications effective, just delivered through a different format.
The key difference in how it works compared to injectable GLP-1s is pharmacokinetic. Because it is a pill that gets absorbed through the digestive system, the drug has a shorter active window than a weekly injection. That is why it needs to be taken daily rather than weekly. For some patients, this daily rhythm actually feels more natural than remembering a once-weekly injection day.
Clinical trial data shows that orforglipron produces weight loss results in the range of 14-15% of body weight over 72 weeks at the highest dose. That puts it in the same conversation as Wegovy (about 15% average loss) and Zepbound (up to 21% at the highest dose). While orforglipron may not match Zepbound at its peak, it is competitive with Wegovy, which is impressive for an oral medication.
Cost and insurance coverage
Pricing for orforglipron is still being established as the drug rolls out to market in April 2026. Eli Lilly has not yet announced a list price, but the small-molecule manufacturing advantage suggests that per-unit production costs are lower than for peptide drugs. Whether that savings gets passed to patients depends on insurance negotiations, manufacturer discount programs, and market competition.
Early expectations are that orforglipron will be priced in the same general range as injectable GLP-1s, potentially slightly below them. Manufacturer savings cards could bring the cost down to $25-50 per month for commercially insured patients, similar to the programs offered by Novo Nordisk for Wegovy and Eli Lilly for Zepbound. Uninsured patients should expect higher out-of-pocket costs, though telehealth platforms may offer competitive cash-pay pricing.
Several telehealth providers are already positioning to offer orforglipron. Platforms like [Ro](/reviews/ro), [Found](/reviews/found), and [Noom](/reviews/noom) have signaled oral GLP-1 access as part of their 2026 strategy. [Hims](/reviews/hims) may also offer it given their existing Novo Nordisk partnership, though availability depends on supply agreements.
Side effects and what to expect
The side effect profile of orforglipron is broadly similar to other GLP-1 receptor agonists. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects tend to be most pronounced during dose escalation and usually diminish as the body adjusts.
Some patients may also experience headache, fatigue, dizziness, or changes in taste. As with injectable GLP-1s, the risk of more serious side effects like pancreatitis, gallbladder disease, and severe gastrointestinal events exists but is uncommon. Patients with a history of pancreatitis or medullary thyroid cancer should avoid orforglipron, consistent with the GLP-1 class warning.
The practical advantage of the pill format is that if side effects become problematic, patients can work with their clinician to adjust the dose more gradually. Because orforglipron is taken daily, dose adjustments can be made in smaller increments than weekly injections, which some patients and clinicians may find easier to manage.
This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.
Orforglipron vs Wegovy vs Zepbound
The natural question for patients comparing options is where orforglipron fits against the established injectable GLP-1s. Wegovy (semaglutide injection) delivers about 15% average body weight loss and has the widest insurance coverage since it has been on the market longest. Zepbound (tirzepatide) delivers up to 21% at the highest dose by targeting both GLP-1 and GIP receptors, making it the most effective option for weight loss, but insurance coverage is still catching up.
Orforglipron sits between them in efficacy but wins on convenience for needle-averse patients. For a detailed head-to-head comparison of the two injectable options, see our [Wegovy vs Zepbound guide](/compare/wegovy-vs-zepbound). For patients specifically interested in oral GLP-1 options, our [best oral GLP-1 comparison](/best-for/best-oral-glp1) covers the emerging landscape.
The bottom line is that orforglipron is a strong option for patients who want meaningful weight loss without injections. It may not be the absolute most powerful drug in the class, but the convenience factor could make it the most practical choice for a large number of people. As with any medication, the best option depends on individual health factors, insurance status, and personal preferences.
Where to get orforglipron online
Several telehealth platforms are expected to offer orforglipron as part of their weight loss programs. [Ro](/reviews/ro) has been among the most vocal about oral GLP-1 access, integrating it into their broader medication menu. [Found](/reviews/found) offers specialist video consults and multiple medication paths, which could make orforglipron one option among several for their patients. [Noom](/reviews/noom) combines behavioral coaching with medication access, which may appeal to patients who want structured support alongside their prescription.
For a broader look at how these and other providers compare across the entire GLP-1 landscape, check out our [next-generation weight loss drugs guide](/guides/next-gen-weight-loss-drugs) and our full [weight loss provider comparison](/weight-loss). The most important thing is to choose a provider that offers real clinical oversight, transparent pricing, and a support model that fits your needs, not just the one that advertises the newest drug first.